These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8777179)

  • 1. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
    Macdonald D; Cairncross G; Stewart D; Forsyth P; Sawka C; Wainman N; Eisenhauer E
    Ann Oncol; 1996 Feb; 7(2):205-7. PubMed ID: 8777179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
    Pipas JM; Meyer LP; Rhodes CH; Cromwell LD; McDonnell CE; Kingman LS; Rigas JR; Fadul CE
    J Neurooncol; 2005 Feb; 71(3):301-5. PubMed ID: 15735921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
    Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
    Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous carboplatin for recurrent malignant glioma: a phase II study.
    Yung WK; Mechtler L; Gleason MJ
    J Clin Oncol; 1991 May; 9(5):860-4. PubMed ID: 1849986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Gururangan S; Vredenburgh J; Sampson JH; Provenzale JM; Walker A; Badruddoja M; Tourt-Uhlig S; Herndon JE; Dowell JM; Affronti ML; Jackson S; Allen D; Ziegler K; Silverman S; Bohlin C; Friedman AH; Bigner DD; Friedman HS
    Neuro Oncol; 2004 Apr; 6(2):134-44. PubMed ID: 15134628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
    Wagner S; Peters O; Fels C; Janssen G; Liebeskind AK; Sauerbrey A; Suttorp M; Hau P; Wolff JE
    J Neurooncol; 2008 Jan; 86(2):175-81. PubMed ID: 17641821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan therapy in adults with recurrent or progressive malignant glioma.
    Friedman HS; Petros WP; Friedman AH; Schaaf LJ; Kerby T; Lawyer J; Parry M; Houghton PJ; Lovell S; Rasheed K; Cloughsey T; Stewart ES; Colvin OM; Provenzale JM; McLendon RE; Bigner DD; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring GL; Miller LL
    J Clin Oncol; 1999 May; 17(5):1516-25. PubMed ID: 10334539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma.
    Phuphanich S; Scott C; Fischbach AJ; Langer C; Yung WK
    J Neurooncol; 1997 Sep; 34(2):193-200. PubMed ID: 9210068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
    Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
    J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
    Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium.
    Hochberg F; Grossman SA; Mikkelsen T; Glantz M; Fisher JD; Piantadosi S
    Neuro Oncol; 2000 Jan; 2(1):29-33. PubMed ID: 11302251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.